Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 852

Similar articles for PubMed (Select 16388519)

1.
2.

Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study.

Recchia F, Sica G, De Filippis S, Saggio G, Rosselli M, Rea S.

Anticancer Drugs. 2002 Apr;13(4):417-24.

PMID:
11984088
3.

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD.

J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46.

5.
6.
7.

Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.

Arriagada R, Lê MG, Spielmann M, Mauriac L, Bonneterre J, Namer M, Delozier T, Hill C, Tursz T.

Ann Oncol. 2005 Mar;16(3):389-96. Epub 2005 Jan 27.

8.

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.

Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thürlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A.

J Clin Oncol. 2000 Feb;18(3):584-90.

PMID:
10653873
9.

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

Colleoni M, Price K, Castiglione-Gertsch M, Goldhirsch A, Coates A, Lindtner J, Collins J, Gelber RD, Thürlimann B, Rudenstam CM.

Eur J Cancer. 1998 Oct;34(11):1693-700.

PMID:
9893654
10.

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B; Zoladex Early Breast Cancer Research Association Study.

J Clin Oncol. 2002 Dec 15;20(24):4628-35.

PMID:
12488406
11.

[Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].

Li HP, Ma LW, Zhang SL, Jia TZ, Deng HJ, Zhang ZH, Liang L, Wang MP, Xiao Y, Cao BS, Chen S, Wang YF.

Zhonghua Zhong Liu Za Zhi. 2006 Nov;28(11):848-51. Chinese.

PMID:
17416008
12.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
13.

Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.

Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL.

J Clin Oncol. 2006 Nov 1;24(31):4956-62.

14.

Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.

Michaud LB, Buzdar AU.

Drugs Aging. 2000 Apr;16(4):261-71. Review.

PMID:
10874521
15.

Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).

Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K; TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).

Anticancer Res. 2002 Jul-Aug;22(4):2325-32.

PMID:
12174922
16.

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.

Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N.

J Natl Cancer Inst. 2001 Jan 17;93(2):112-20.

17.

Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.

Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K.

J Clin Oncol. 2007 Jun 20;25(18):2509-15.

19.

Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.

Adjuvant Breast Cancer Trials Collaborative Group.

J Natl Cancer Inst. 2007 Apr 4;99(7):506-15.

20.

Adjuvant chemotherapy in 780 patients with early breast cancer: 10-year data from Saudi Arabia.

Ibrahim EM, Ezzat AA, Rahal MM, Raja MM, Ajarim DS.

Med Oncol. 2005;22(4):343-52.

PMID:
16260851
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk